These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35810311)

  • 1. An observational, non-interventional study for the follow-up of patients with amyloidosis who received miridesap followed by dezamizumab in a phase 1 study.
    Richards D; Millns H; Cookson L; Lukas MA
    Orphanet J Rare Dis; 2022 Jul; 17(1):259. PubMed ID: 35810311
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacodynamic evaluation and safety assessment of treatment with antibodies to serum amyloid P component in patients with cardiac amyloidosis: an open-label Phase 2 study and an adjunctive immuno-PET imaging study.
    Wechalekar A; Antoni G; Al Azzam W; Bergström M; Biswas S; Chen C; Cheriyan J; Cleveland M; Cookson L; Galette P; Janiczek RL; Kwong RY; Lukas MA; Millns H; Richards D; Schneider I; Solomon SD; Sörensen J; Storey J; Thompson D; van Dongen G; Vugts DJ; Wall A; Wikström G; Falk RH
    BMC Cardiovasc Disord; 2022 Feb; 22(1):49. PubMed ID: 35152886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB; Cookson LM; Barton SV; Liefaard L; Lane T; Hutt DF; Ritter JM; Fontana M; Moon JC; Gillmore JD; Wechalekar A; Hawkins PN; Pepys MB
    Sci Transl Med; 2018 Jan; 10(422):. PubMed ID: 29298867
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB; Cookson LM; Berges AC; Barton SV; Lane T; Ritter JM; Fontana M; Moon JC; Pinzani M; Gillmore JD; Hawkins PN; Pepys MB
    N Engl J Med; 2015 Sep; 373(12):1106-14. PubMed ID: 26176329
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Pentraxins 1975-2018: Serendipity, Diagnostics and Drugs.
    Pepys MB
    Front Immunol; 2018; 9():2382. PubMed ID: 30459761
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of a Single Intravenous Dose of Miridesap in Healthy Japanese Subjects.
    Ino H; Doi Y; Liefaard L; Cookson L; Chen C; Itoh H; Igarashi H; Nakano A
    Clin Pharmacol Drug Dev; 2019 Jul; 8(5):612-618. PubMed ID: 30556959
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized phase I trial HIV-CORE 003: Depletion of serum amyloid P component and immunogenicity of DNA vaccination against HIV-1.
    Borthwick NJ; Lane T; Moyo N; Crook A; Shim JM; Baines I; Wee EG; Hawkins PN; Gillmore JD; Hanke T; Pepys MB
    PLoS One; 2018; 13(5):e0197299. PubMed ID: 29772028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Novel methods to determine complement activation in human serum induced by the complex of Dezamizumab and serum amyloid P.
    Ma J; Liu Q; White JR
    J Biol Chem; 2021 Oct; 297(4):101136. PubMed ID: 34461096
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification, preclinical profile, and clinical proof of concept of an orally bioavailable pro-drug of miridesap.
    Richards D; Bamford M; Liefaard L; Haque N; Lewis G; Storey J; Fernando D; Kumar S; Thompson D; Holmes DS
    Br J Pharmacol; 2020 Apr; 177(8):1853-1864. PubMed ID: 31877231
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sustained pharmacological depletion of serum amyloid P component in patients with systemic amyloidosis.
    Gillmore JD; Tennent GA; Hutchinson WL; Gallimore JR; Lachmann HJ; Goodman HJ; Offer M; Millar DJ; Petrie A; Hawkins PN; Pepys MB
    Br J Haematol; 2010 Mar; 148(5):760-7. PubMed ID: 20064157
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Disappearance of immunoglobulins from persistent renal amyloid deposits following stem cell transplantation for heavy-and light-chain amyloidosis.
    Safadi S; Saad A; Quint PS; Sethi S; Leung N; Kurtin P; Nasr SH
    Nephrol Dial Transplant; 2015 Jul; 30(7):1151-5. PubMed ID: 25796445
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies to human serum amyloid P component eliminate visceral amyloid deposits.
    Bodin K; Ellmerich S; Kahan MC; Tennent GA; Loesch A; Gilbertson JA; Hutchinson WL; Mangione PP; Gallimore JR; Millar DJ; Minogue S; Dhillon AP; Taylor GW; Bradwell AR; Petrie A; Gillmore JD; Bellotti V; Botto M; Hawkins PN; Pepys MB
    Nature; 2010 Nov; 468(7320):93-7. PubMed ID: 20962779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunoradiometric assay for human serum amyloid P component.
    Millar DJ; Hutchinson WL; Pepys MB
    J Immunol Methods; 2011 Aug; 371(1-2):18-24. PubMed ID: 21708157
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Kinetic studies with iodine-123-labeled serum amyloid P component in patients with systemic AA and AL amyloidosis and assessment of clinical value.
    Jager PL; Hazenberg BP; Franssen EJ; Limburg PC; van Rijswijk MH; Piers DA
    J Nucl Med; 1998 Apr; 39(4):699-706. PubMed ID: 9544684
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Target Mediated Drug Disposition Model of CPHPC in Patients with Systemic Amyloidosis.
    Sahota T; Berges A; Barton S; Cookson L; Zamuner S; Richards D
    CPT Pharmacometrics Syst Pharmacol; 2015 Feb; 4(2):e15. PubMed ID: 26225229
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacological removal of serum amyloid P component from intracerebral plaques and cerebrovascular Aβ amyloid deposits in vivo.
    Al-Shawi R; Tennent GA; Millar DJ; Richard-Londt A; Brandner S; Werring DJ; Simons JP; Pepys MB
    Open Biol; 2016 Feb; 6(2):150202. PubMed ID: 26842068
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted pharmacological depletion of serum amyloid P component for treatment of human amyloidosis.
    Pepys MB; Herbert J; Hutchinson WL; Tennent GA; Lachmann HJ; Gallimore JR; Lovat LB; Bartfai T; Alanine A; Hertel C; Hoffmann T; Jakob-Roetne R; Norcross RD; Kemp JA; Yamamura K; Suzuki M; Taylor GW; Murray S; Thompson D; Purvis A; Kolstoe S; Wood SP; Hawkins PN
    Nature; 2002 May; 417(6886):254-9. PubMed ID: 12015594
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits.
    Popkova T; Hajek R; Jelinek T
    Br J Haematol; 2020 Apr; 189(2):228-238. PubMed ID: 32072615
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Serum amyloid P component scintigraphy and turnover studies for diagnosis and quantitative monitoring of AA amyloidosis in juvenile rheumatoid arthritis.
    Hawkins PN; Richardson S; Vigushin DM; David J; Kelsey CR; Gray RE; Hall MA; Woo P; Lavender JP; Pepys MB
    Arthritis Rheum; 1993 Jun; 36(6):842-51. PubMed ID: 8507227
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prospective and serial study of primary amyloidosis with serum amyloid P component scintigraphy: from diagnosis to prognosis.
    Hachulla E; Maulin L; Deveaux M; Facon T; Blétry O; Vanhille P; Wechsler B; Godeau P; Levesque H; Hatron PY; Huglo D; Devulder B; Marchandise X
    Am J Med; 1996 Jul; 101(1):77-87. PubMed ID: 8686719
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.